Company Overview

Dogwood Therapeutics (Nasdaq DWTX) is a development-stage biotechnology company focused on advancing novel therapeutics for pain and fatigue illness.

Dogwood’s lead product, Halneuron®, is a highly selective sodium channel blocker being developed to treat moderate-to-severe chemotherapy induced neuropathic pain (CINP), cancer related pain (CRP), and other pain indications. Halneuron is a small molecule that reduces pain transmission by blocking NAv 1.7, a sodium channel involved with the initiation and conduction of nerve impulses in the peripheral nervous system.

Dogwood is also pioneering the antiviral therapies IMC-1 and IMC-2 to treat diseases associated with a viral triggered abnormal immune response such as Long-COVID (“LC”) and fibromyalgia (“FM”). Overactive immune response related to activation of tissue resident herpesvirus has been postulated to be a potential root cause of chronic illnesses such as FM, irritable bowel syndrome, LC, chronic fatigue syndrome and functional somatic syndrome, all of which are characterized by a waxing and waning manifestation of disease, often triggered by events which compromise the immune system.